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Nanobodies are single-domain fragments of camelid
antibodies that are emerging as versatile tools in
biotechnology. We describe here the interactions of a
specific nanobody, NbSyn87, with themonomeric and
fibrillar forms of α-synuclein (αSyn), a 140-residue
protein whose aggregation is associated with Parkin-
son's disease. We have characterized these interac-
tions using a range of biophysical techniques,
including nuclear magnetic resonance and circular
dichroism spectroscopy, isothermal titration calorime-
try and quartz crystal microbalance measurements. In
addition, we have compared the results with those that
we have reported previously for a different nanobody,
NbSyn2, also raised against monomeric αSyn. This
comparison indicates that NbSyn87 and NbSyn2 bind
with nanomolar affinity to distinctive epitopes within
the C-terminal domain of soluble αSyn, comprising
approximately amino acids 118–131 and 137–140,
respectively. The calorimetric and quartz crystal
microbalance data indicate that the epitopes of both
nanobodies are still accessible when αSyn converts
into its fibrillar structure. The apparent affinities and
other thermodynamic parameters defining the binding
between the nanobody and the fibrils, however, vary
significantly with the length of time that the process of
fibril formation has been allowed to progress and with
the conditions under which formation occurs, indicat-
ing that the environment of the C-terminal domain ofJ. Mol. Biol. (2013) 425, 2397–2411
2398 Nanobodies and α-Synuclein Fibril FormationαSyn changes as fibril assembly takes place. These results demonstrate that nanobodies are able to target forms
of potentially pathogenic aggregates that differ fromeach other in relativelyminor details of their structure, suchas
those associated with fibril maturation.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Parkinson's disease (PD) is the second most
common human neurodegenerative disorder affect-
ing over 1% of the global population over 60 years of
age.1 The symptoms of PD, which include resting
tremor, slowness of movement, muscular rigidity and
impairment of postural reflex, are caused by a
progressive loss of dopaminergic neurons in the
substantia nigra pars compacta region of the brain.2
Several lines of evidence suggest that the misfolding
of the pre-synaptic protein α-synuclein (αSyn) into
fibrillar aggregates plays a key role in the develop-
ment of PD pathogenesis, notably, that aggregated
αSyn is the major protein component found in Lewy
bodies and Lewy neurites, which are the main
pathological hallmarks of PD.3–5 Furthermore, a
number of geneticmutations that result in substitution
of one amino acid for another, as well as triplication
of the αSyn gene, are correlated with early onset
of PD.6–10 The misfolding of αSyn has also been
shown to be involved in a variety of other
neurological disorders, including dementia with
Lewy bodies, multiple system atrophy and neuro-
axonal dystrophy.11–15
Although the aggregation of αSyn into amyloid
fibrils appears to be one of the key processes
underlying PD pathogenesis and other synucleino-
pathies, the precise mechanism leading to neurode-
generation is not yet fully understood. Increasing
evidence suggests, however, that the oligomeric
precursors and pre-fibrillar amyloid species, rather
than the mature fibrils, are primarily responsible for
cytotoxicity and neuronal cell death.5,16–19 In its
monomeric form, αSyn is a soluble, intrinsically
disordered protein of 140 amino acids20 that can
adopt an α-helical conformation when bound to lipid
vesicles;21,22 in addition, a number of other possible
conformational states have been discussed.23–25
The biological function of αSyn remains unclear,
although it has been suggested to play a role in
modulating synaptic plasticity, neurotransmitter re-
lease and pre-synaptic vesicle pool size.26–28
Three distinct regions can be discerned within the
αSyn sequence: (1) a positively charged N-terminal
segment containing imperfect repeats of 11 residues
(each with a high propensity to form amphipathic
helices; residues 1–60), (2) a central amyloidogenic
region termed the non-amyloid component region
(residues 61–95) and (3) a polar and negatively
charged C-terminal region (residues 96–140).20,21
Although the monomeric form of αSyn is intrinsicallydisordered in solution, it adopts a predominantly β-
sheet conformation in its fibrillar form.29 Several
studies have shown that amyloid fibrils of αSyn
consist of individual intertwined protofilaments, each
consisting of a five-stranded β-sheet, leaving resi-
dues 1–30 and 110–140 highly flexible and solvent
accessible.30–35 Although these C- and N-terminal
regions are not directly involved in the central core of
the protofilaments and do not adopt a β-sheet
conformation, their interactions have been found to
be important for the stabilization of protofilaments
and amyloid fibrils.34
In order to understand the mechanisms that
underlie cellular toxicity and disease, it is essential
to gain structural information about the variety of
aggregated species that are associated with amyloid
formation.36 Acquiring this information is, however,
extremely challenging, as most conventional struc-
tural techniques require concentrated and homoge-
neous samples. Such samples are very difficult to
obtain for each individual form of intermediate
species involved in the process of fibril formation,
primarily because of their frequently transient nature
within a highly heterogeneous mixture of monomeric
and aggregated species.5 The development of
specific and sensitive molecular probes for the
characterization of distinct forms of amyloid species
is therefore an important goal, and it has been shown
that the use of single-domain heavy-chain antibody
fragments, commonly known as nanobodies, can be
extremely promising for this purpose.37–45
We have recently demonstrated that it is possible
to raise nanobodies against the monomeric form of
αSyn by reporting and characterizing the binding of
one nanobody, NbSyn2, which recognizes the last
four residues (137–140) of the C-terminal domain of
the protein.40,46 In the present report, we describe
the characterization and binding properties of a
second nanobody raised against αSyn, NbSyn87,
using circular dichroism (CD) and nuclear magnetic
resonance (NMR) spectroscopy, isothermal titration
calorimetry (ITC) and quartz crystal microbalance
(QCM) techniques. The analysis shows that
NbSyn87 recognizes a different epitope from that
of NbSyn2, which is again located in the C-terminal
region but further away from the C-terminus, and
comprises residues 118–131. Experiments using
ITC and QCM reveal that, like NbSyn2, NbSyn87
binds not only to the monomeric protein but also to
the fibrillar form, indicating that residues 118–131
are solvent accessible in this state. If the fibrils are
left to evolve and mature in solution for prolonged
2399Nanobodies and α-Synuclein Fibril Formationperiods of time, however, the nature of the binding of
both NbSyn87 and NbSyn2 to the fibrils changes,
leading to a lower apparent affinity for their epitopes,
that are displayed on the fibril surfaces, thus
suggesting the possibility that conformational rear-
rangements of these regions of the αSyn molecule
may take place upon the maturation of the fibrillar
state. We describe here the characterization of the
binding of the nanobodies to amyloid fibrils and the
nature of the time-dependent changes associated
with fibril maturation.Results
Identification of the nanobody binding regions
of αSyn by NMR spectroscopy
NbSyn87 was obtained after phage display selec-
tion of a single-domain camelid antibody library
originating from a llama immunized with αSyn. The
amino acid sequence of NbSyn87 differs significant-
ly from the previously reported NbSyn2 (Fig. S1).Fig. 1. NbSyn87 and NbSyn2
bind distinctive regions within the
C-terminal domain of αSyn. (a)
15N–1H HSQC spectra of uniformly
15N-labeled αSyn upon binding to
NbSyn87 and NbSyn2, respective-
ly, shown in green and blue. The
unbound form of αSyn is represent-
ed in red. (b) Chemical shift
changes in the free and bound
states; the changes are defined as
[0.04 × (δ15Nfree − δ15Nbound)2 +
(δ1Hfree − δ1Hbound)2]1/2, the insets
in both panels show a more detailed
view of the smaller chemical shift
perturbations for the resonances of
residues 100–140 (green, NbSyn2;
blue, NbSyn87). (c) Intensities of
the HSQC cross-peaks of bound
compared to free αSyn (Ibound/Ifree)
(green, NbSyn2; blue, NbSyn87).
Fig. 2. Characterization of the interactions of NbSyn87 and NbSyn2 with full-length monomeric αSyn by ITC and CD.
ITC data for (a) NbSyn87 and (b) NbSyn2 binding to monomeric αSyn at 25 °C in PBS buffer. (c) ΔGb, ΔHb and −TΔSb
measured for the binding of NbSyn87 (blue) and NbSyn2 (green). (d) Variation of ΔHb as a function of temperature; these
data enable the determination of ΔCp,b values. The values obtained for NbSyn87 (blue) and NbSyn2 (green) bound to full-
length αSyn are, respectively, −0.41 ± 0.01 and −0.23 ± 0.12 kcal mol−1 K−1. Far-UV CD spectra obtained for (e)
NbSyn87 and (f) NbSyn2; in each case, the traces are shown for the nanobody (brown), αSyn (red) and αSyn:nanobody
complex (green) at 25 °C in PBS buffer. The difference spectrum [(αSyn:nanobody complex) − (nanobody + αSyn)] is
shown as a blue dotted line.
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Table 1. Thermodynamic parameters of nanobody binding to monomeric αSyn, C-terminal peptides and fibrillar structures
Nanobodies Forms of αSyn
T
(°C)
n
([nb] × [αSyn]−1) Kd (nM)
ΔHb
(kcal mol−1)
−TΔSb
(kcal mol−1)
ΔGb
(kcal mol−1)
ΔCp,b
(kcal mol−1 K−1)
NbSyn87 Monomer 20a 0.95 ± 0.01 10.1 ± 0.8 −15.4 ± 0.1 4.7 ± 0.1 −10.7 ± 0.1 −0.41 ± 0.01
25b 0.94 ± 0.01 14.2 ± 8.4 −17.6 ± 0.4 6.9 ± 0.5 −10.8 ± 0.4
30a 1.00 ± 0.01 52.6 ± 5.5 −19.5 ± 0.1 9.4 ± 0.1 −10.1 ± 0.1
37a 0.95 ± 0.01 41.9 ± 4.8 −22.4 ± 0.2 11.9 ± 0.2 −10.5 ± 0.1
Peptides 118–140 25a 0.91 ± 0.01 61.7 ± 16.7 −17.0 ± 0.2 7.1 ± 0.2 −9.8 ± 0.2
Peptides 118–131 25a 0.98 ± 0.04 (1.37±0.30) × 103 −12.9 ± 0.8 4.9 ± 0.8 −8.0 ± 0.1
Peptides 118–129 25b 0.98 ± 0.03 (2.35 ± 0.46) × 103 −8.6 ± 0.6 0.9 ± 0.6 −7.7 ± 0.1
Fibril, F0,2d 25
b 0.85 ± 0.01 94.8 ± 14.0 −21.9 ± 0.3 12.3 ± 0.3 −9.6 ± 0.1
Fibril, F0,6d 25
b 0.87 ± 0.02 546.5 ± 105.2 −23.9 ± 0.9 15.3 ± 0.9 −8.6 ± 0.1
NbSyn2 Monomerc 20a 0.99 ± 0.01 106.1 ± 21.1 −18.0 ± 0.5 8.7 ± 0.5 −9.4 ± 0.1 −0.23 ± 0.12
25a 0.93 ± 0.01 129.8 ± 22.7 −19.1 ± 0.5 9.7 ± 0.5 −9.4 ± 0.1
30a 0.87 ± 0.01 107.9 ± 18.4 −20.4 ± 0.4 10.7 ± 0.4 −9.7 ± 0.1
37a 0.91 ± 0.03 264.4 ± 69.0 −21.8 ± 1.2 12.5 ± 1.3 −9.3 ± 0.2
Peptides 136–140c 25a 0.99 ± 0.01 190.4 ± 30.0 −12.4 ± 0.4 3.3 ± 0.4 −9.2 ± 0.1
Fibril, F0,2d 25
b 0.91 ± 0.01 260.0 ± 42.6 −19.5 ± 0.5 10.5 ± 0.5 −9.0 ± 0.1
Fibril, F0,6d 25
b 0.92 ± 0.02 387.2 ± 67.2 −21.1 ± 0.7 12.4 ± 0.7 −8.7 ± 0.1
a Single experiment, fitted errors.
b Average of three replicates, experimental errors.
c Results from De Genst et al.40
2401Nanobodies and α-Synuclein Fibril FormationThe region of αSyn that binds to NbSyn87 was
mapped using 1H–15N heteronuclear single quan-
tum coherence (HSQC) spectroscopy and was
compared to the region previously identified for
NbSyn2.40 Solutions of unlabeled NbSyn87 were
titrated into samples containing 15N isotopically
enriched αSyn, and the resulting spectral changes
were closely similar to those observed previously
with NbSyn2; the titrations of both nbSyn2 and
NbSyn87 resulted in either broadening or chemical
shift perturbations of resonances of residues locat-
ed only in the C-terminal region of αSyn (Fig. 1),
and the NMR data therefore indicate that both
nanobodies bind within the C-terminal region of
αSyn. The residues that display the most strongly
perturbed resonances upon binding include 118–
137 for NbSyn87 and 130–140 for NbSyn2,
indicating that the two nanobodies have significantly
different epitopes.
Detection and quantification of the interactions
of the nanobodies with monomeric αSyn by ITC
We used ITC to measure the thermodynamic
parameters of the interactions of both nanobodies
with αSyn (Fig. 2). The ITC data reveal for both
nanobodies a 1:1 interaction with soluble monomeric
αSyn and dissociation constants (Kd) at 25 °C of
14.2 ± 8.4 and 129.8 ± 22.7 nM (Table 1), respec-
tively, for NbSyn87 and NbSyn2. The data further
reveal that both nanobody:αSyn interactions are
predominantly enthalpically driven (Fig. 2c; Table 1)
and that the values of the thermodynamic parameters
measured for the interactions are typical of the values
found for other antigen:antibody interactions.40,47
In order to determine the changes in heat
capacity upon binding (ΔCp,b), we performed ITCexperiments at temperatures ranging between
20 °C and 37 °C. As shown in Fig. 2d, a plot of
the values of the binding enthalpy (ΔHb) versus
temperature (T) reveals an effectively linear depen-
dency, which enables us to estimate ΔCp,b by linear
regression analysis, resulting in values −0.41 ±
0.01 and −0.23 ± 0.12 kcal mol−1 K−1 for NbSyn87
and NbSyn2, respectively (Table 1). ΔCp,b values
have been shown to be correlated to the change in
solvent-accessible surface area (ΔASA) upon
binding.48 The fact that the ΔCp,b value for the
binding of NbSyn87 is very significantly larger than
that for the binding of NbSyn2 suggests that a larger
number of αSyn residues are involved in the binding
of NbSyn87 compared to the binding of NbSyn2 to
αSyn, a conclusion that is in agreement with the
NMR results (Fig. 1). The absence of detectable
curvature in the plot of ΔHb values as a function of
temperature for the binding of the nanobodies to
monomeric αSyn suggests that no significant
additional conformational changes are induced
upon complex formation for either nanobody.
Secondary structure changes induced in αSyn
by the binding of NbSyn87 and NbSyn2
To explore further whether secondary structure
changes occur upon binding of the nanobodies to
αSyn, we recorded far-UV CD spectra of αSyn and
both nanobodies individually, as well as that of αSyn
with equimolar mixtures of each nanobody (Fig. 2e
and f). The disordered nature of monomeric αSyn is
reflected in a CD spectrum typical for a protein
lacking regular secondary structure elements.20 By
contrast, the CD spectra of the nanobodies are
indicative of species rich in β-sheet structure and
are typical of the spectra of proteins with an
2402 Nanobodies and α-Synuclein Fibril Formationimmunoglobulin fold.49 The CD spectrum of the
NbSyn87:αSyn complex (as with the spectra reported
previously for the NbSyn2:αSyn interaction40) is
essentially the sum of the spectra corresponding to
the two individual protein components, indicating that
changes in secondary structure upon complex
formation, if present, are of very limited extent. In
particular, there is no evidence that αSyn becomes
significantly more structured upon binding, suggest-
ing that the nanobodies bind to a significantly
disordered epitope on αSyn. These findings are
further corroborated by the observation that the Cα
and Cβ chemical shifts of αSyn, which were obtained
from three-dimensional (3D) NMR measurements for
the purpose of assigning the amide resonances of
the αSyn HSQC spectra (Materials and Methods), did
not change significantly upon addition of the nano-
bodies and remain close to the random-coil values
found for native αSyn50 (Fig. S2).
Delineation of the epitope of NbSyn87 by
peptide mapping
In order to determine the epitope of NbSyn87 in
more detail, we designed a series of peptides of
different lengths, spanning stretches of the se-
quence of αSyn from residues 118 to 140 (Fig. 3)Fig. 3. Epitope mapping of NbSyn87 by ITC. (a) Based o
resonances of the amino acids of αSyn that are perturbed u
underlined in blue and green in the αSyn sequence. Residue
HSQC spectra were found to be perturbed upon binding to the
confirmed to be involved in the binding by additional ITC experim
NbSyn2 and a C-terminal peptide of αSyn40 are indicated
component regions are also indicated in the αSyn sequence. (b
of NbSyn87 in more detail by ITC; those retaining the ability to
detectable binding are shown in red. (c) Binding affinities of Nb
variant (residues 1–120) and the various peptides shown in (c
residues 118–123, 119–124, 120–125, 121–126, 122–127, 12whose 1H and 15N resonances are perturbed in the
HSQC spectrum upon binding to the nanobody
(Fig. 1). We then measured the thermodynamic
parameters of the NbSyn87 binding to each peptide
using ITC. The results (Fig. 3 and Table 1) reveal
that NbSyn87 binds to the peptide corresponding to
residues 118–140 of αSyn with a Kd value of
61.7 ± 16.7 nM, which constitutes a 6-fold lower
affinity compared to the interaction of the wild-type
protein with NbSyn87, which might reflect the loss
of a weak contact contributed by a residue
preceding residue 118 in the sequence of αSyn.
We find also that a truncated variant of αSyn,
lacking residues 121–140, does not show any
detectable binding to the nanobody by ITC
(Fig. 3c). The peptide corresponding to residues
118–131 of αSyn, however, binds to NbSyn87 with
a Kd of 1.37 × 10
3 ± 0.30 × 103 nM. The latter
peptide therefore has a 20-fold lower affinity
compared to the peptide corresponding to residues
118–140 of αSyn. This indicates that some contacts
are made between NbSyn87 and residues within
the region 131–140; however, they contribute only a
moderate ±1.8 kcal mol−1 to interaction. However,
the peptide corresponding to residues 120–131
shows no detectable binding. Taken together, these
results indicate that the majority of the epitope ofn the 15N–1H HSQC results shown in Fig. 1, the amide
pon binding of NbSyn87 and NbSyn2 are, respectively,
s of αSyn for which the amide resonances in the 15N-1H
nanobodies are indicated with dotted lines. Those residues
ents or the previously published crystal structure involving
with a continuous line. The fibril core and non-amyloid
) Peptides of various lengths designed to map the epitope
bind NbSyn87 are shown in blue, while those that show no
Syn87 for full-length αSyn, a C-terminally truncated αSyn
). The peptides that show no detectable binding comprise
3–128 and 124–129.
2403Nanobodies and α-Synuclein Fibril FormationNbSyn87 is located between residues 118 and 131
of αSyn (Fig. 3b) and that the residues 118 and 119
are critical for binding. By contrast, the crystal
structure of NbSyn2 bound to a peptide corre-
sponding to the last 9 amino acids of αSyn40
reveals that NbSyn2 binds to a different epitope,
comprising residues 137–140, as shown in Fig. 3.Observation of nanobody:fibril binding by QCM
There is a considerable body of evidence indicat-
ing that the C-terminal domain of αSyn is not directly
involved in the formation of the β-sheet core of αSyn
fibrils and indeed that this region of the sequence is
highly solvent exposed in the fibrillar structure.30–35
We therefore examined whether or not either or both
of the nanobodies studied here could bind to the
fibrillar form of αSyn using QCM, a technique that can
monitor molecular interactions by change of surface-
boundmass51–53 (Fig. 4). TheQCM sensors contain-
ing surface-attached αSyn fibril fragments were
exposed to a solution containing a saturating
concentration of NbSyn87. Once binding equilibrium
was reached, we exposed the sensors to a second
solution containing an equimolar mixture of NbSyn87
and NbSyn2 at saturating concentrations (Fig. 4a).
The results show that both nanobodies can bind to
αSyn fibrils, confirming the supposition that the C-
terminal domain is exposed to the solvent in the
fibrillar form of αSyn. In addition, the results show
that both nanobodies can bind simultaneously to the
fibrils, confirming the NMR and ITC results described
previously and demonstrating that both nanobodies
possess distinctive, non-overlapping epitopes. In
addition, a QCM sensor to which fibrils generated
from the 1–120 (truncated) αSyn variant, that is, the
protein lacking residues 121–140 and therefore
lacking the large majority of the epitope identified
for NbSyn87 and NbSyn2, had been attached wasFig. 4. Characterization of the interactions of NbSyn87 an
showing the binding of NbSyn87 to αSyn fibrils followed b
nanobodies. The solutions contained saturating concentration
Negative control experiment where a solution containing both
into contact with a sensor containing fibrils of the C-terminally tr
compared upon addition of PBS buffer only.used to probe the specificity of the nanobody
binding. As shown in Fig. 4b, no detectable binding
was observed upon addition of a mixture containing
both NbSyn87 and NbSyn2 to the QCM sensor,
which is similar to the signal obtained when adding a
solution of phosphate-buffered saline (PBS) only.
These results confirm the high binding specificity of
the antibody fragment to its C-terminal epitope
displayed on the full-length αSyn molecules.
Interaction of nanobodies with αSyn fibrils
studied by ITC
In the light of the results of the QCM experiments,
we characterized the binding of the nanobodies to
αSyn fibrils in greater detail by means of ITC and
explored whether we could use nanobodies within
an ITC approach to detect differences between
different preparations of fibrils. We chose to study
unseeded fibrils (F0 fibrils) that were harvested after
2 days (F0,2d) and after 6 days (F0,6d), respectively.
In addition, we investigated the binding properties of
fibrils that were seeded with F0,6d seeds to generate
seeded fibrils (F1 fibrils) that were harvested after
2 days of incubation (F1,2d). Prior to the ITC
experiments, the samples were analyzed by trans-
mission electron microscopy (TEM), thioflavin-T
(ThT) fluorescence measurements and dot blot
analysis using a sequence-specific anti-αSyn anti-
body. The dot blot analysis confirmed that the
supernatant of centrifuged fibril samples did not
contain any detectable soluble αSyn species, such
as the αSyn monomer (Fig. 5). TEM analysis
showed that, apart from small differences in fibril
length, no clear morphological differences were
observed between the different fibril samples. The
ThT binding assays revealed only slight variations
between the fibril samples, resulting in fluorescence
intensities of 260.4 ± 9.9, 285.9 ± 6.8 and 326.3 ±
6.9 AU (absorbance units) for F0,2d, F0,6d and F1,2dd NbSyn2 with αSyn fibrils by QCM. (a) QCM experiment
y the binding of an equimolar mixture containing both
s of nanobody, as described in Materials and Methods. (b)
NbSyn87 and NbSyn2 at 5μM concentrations was brought
uncated αSyn variant (residues 1–120), which was equally
2404 Nanobodies and α-Synuclein Fibril Formationfibrils, respectively (Fig. 5). TEM imaging and ThT
fluorescence measurements (Figs. S3 and S4) on
ITC samples collected after the measurements
confirmed the integrity of the fibrils.
A first set of ITC experiments was performed with
F0,2d fibrils. Titration of either NbSyn2 or NbSyn87
into an F0,2d sample led to the observation of
significant heat output (Fig. 6), the amplitude of
which gradually decreased during the titration;
detailed analysis shows that the data fit well to a
simple bimolecular binding model. By determining
the total concentration of αSyn molecules in the
fibrillar form (Materials and Methods), we could
define apparent thermodynamic parameters for
αSyn binding to the two nanobodies (Table 1). This
analysis shows that the apparent affinities of both
nanobodies for F0,2d fibrils are lower than those
measured for the soluble monomer of αSyn, result-
ing in 6.7 ± 4.1-fold and 2.0 ± 0.5-fold differences in
the binding constants compared to the monomer
interaction for NbSyn87 and NbSyn2, respectively.
In contrast to NbSyn2, the NbSyn87 interaction with
fibrils showed a marked decrease in the apparent
enthalpy of binding (ΔΔH = −4.2 ± 0.5 kcal mol−1)
compared to that observed with monomeric αSyn.
The values of the binding stoichiometries of bothnanobody:fibril interactions were found to be 0.85 ±
0.01 and 0.91 ± 0.01 for NbSyn87 and NbSyn2,
respectively. This observation indicates that
NbSyn87 and NbSyn2 have the ability to occupy
over 85% of the binding sites displayed on αSyn
monomers incorporated into the F0,2d fibrils, reveal-
ing almost complete accessibility of the C-terminal
region in this particular fibrillar state.
Analysis of ITC experiments using F0,6d fibrils
reveals a further decrease in the apparent Kd and
apparent ΔH values compared to F0,2d fibrils for both
nanobodies, resulting in a 5.8 ± 1.4-fold and 1.5 ±
0.4-fold decrease of the Kd values and apparent
ΔΔH values of −2.0 ± 1.0 and −1.6 ± 0.9 kcal mol−1
for NbSyn87 and NbSyn2, respectively. No signifi-
cant changes in the apparent stoichiometries of
binding were detected between the two fibril samples
(F0,2d and F0,6d).
ITC experiments were also performed with fibrils
that were obtained after a 2-day incubation of
monomeric αSyn in the presence of 1% seeds of
the F0,6d fibrils, referred to as F1,2d fibrils (Materials
and Methods). Interestingly, for these F1,2d fibrils, a
bimodal profile of the integrated heat versus molar
equivalents of injected NbSyn87 is observed in
sharp contrast to the monotonic binding profilesFig. 5. Characterization of the
seeded and unseeded αSyn fibrils
at different stages of maturation. (a)
TEM images of unseeded (F0) fibril
samples isolated after 2 days
(F0,2d) and 6 days (F0,6d) of incuba-
tion and those of seeded (F1) fibril
samples isolated after 2 days of
incubation (F1,2d). (b) Fluorescence
intensities following addition of ThT
to the different fibril samples. (c)
Dot blot measurements using an
anti-αSyn primary antibody to probe
for monomeric αSyn present in
samples of both the harvested fibril
pellet (dissolved in 4 M Gdn-HCl)
and the isolated supernatant.
Fig. 6. Characterization of the interactions of NbSyn87 andNbSyn2with seeded and unseeded αSyn fibrils at different stages ofmaturation by ITC. ITC experiments with (a)
NbSyn87 and (b) NbSyn2 added tomonomeric αSyn (panel 1) and unseeded (F
0
) fibril samples isolated after 2 days (F
0,2d
, panel 2) and 6 days (F
0,6d
, panel 3) of incubation at
25 °C, compared with seeded (F
1
) fibril samples isolated after 2 days (F1,2d, panel 4) of incubation. Fibrils were formed and harvested as described in Materials and Methods.
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2406 Nanobodies and α-Synuclein Fibril Formationobserved for the F0 generation fibrils. TEM imaging
(Fig. S3), ThT fluorescence measurements (Fig. S4)
and dot blot analysis confirmed that this observation
is unlikely to originate from the release of monomeric
protein during the experiment (Fig. S5). The bimodal
profile of the binding isotherm precluded data fitting
with a simple bimolecular binding model and
suggests the presence of non-equivalent binding
sites, resulting in competition, possibly involving
cooperativity, for the binding of the nanobodies as
more of these molecules bind to complete saturation
of their epitopes on the fibrillar structures. Bimodality
was also observed for NbSyn2 but was less
pronounced than for the binding of NbSyn87 (Fig. 6).Discussion
NbSyn87 and NbSyn2 recognize distinctive
epitopes located in the C-terminal domain
of αSyn
The ITC and NMR measurements that we have
described demonstrate that both NbSyn87 and
NbSyn2, which were obtained by immunization and
phage display technology, as described in our
previous study,40 recognize the C-terminal region of
αSyn in its solution state with a 1:1 binding stoichiom-
etry and that they differ in affinity by an order of
magnitude. Epitope mapping by NMR, ITC and QCM
indicates, however, that NbSyn87 andNbSyn2 bind to
different epitopeswithin theC-terminal region ofαSyn.
Based on the crystal structure obtained for NbSyn2 in
complex with the C-terminal peptide of its epitope,40
we conclude that only the last four amino acids of
αSyn (137–140) are in direct contact with the nano-
body in the form of a linear epitope, with the carboxyl
group of Ala140 deeply buried within a binding pocket
formed by residues of the complementarity-determin-
ing region 3 and complementarity-determining region
2 binding loops of the nanobody. By contrast, the
HSQC experiments on NbSyn87 and epitope map-
ping experiments using designed peptides and ITC
suggest that, compared to NbSyn2, this nanobody
binds to a larger but distinct segment of the αSyn
sequence, approximately comprising residues 118–
131. The higher affinity of NbSyn87 compared to
NbSyn2 can be attributed to the differences in size
between the two αSyn epitopes.
The CD experiments that we have performed show
the absence of any significant secondary structure
changes in the complex between αSyn and NbSyn87
(Fig. 2), as was also found previously for NbSyn2,
suggesting that the epitope does not adopt a regular
secondary structure on binding. Linear antibody
epitopes are typically composed of 5–12 residues.54
Given the number of residues found to be involved
upon binding of NbSyn87 by NMR and ITC, it seemslikely that the epitope region of the protein complex
might undergo some compaction without the forma-
tion of regular secondary structure. The larger
epitope for NbSyn87 compared to NbSyn2 is
consistent with the ΔCp,b values obtained by ITC,
as shown in Fig. 2c, asΔCp,b is related toΔASA upon
protein:protein complex formation.48
Differential binding of NSyn87 and NbSyn2 to
αSyn fibrils suggests the existence of structural
variation within the C-terminal domain of the fibrils
By characterizing the fibrillar interactions of
NbSyn87 and NbSyn2 by ITC, we have gained
some insights into the fibrillar structure of αSyn, in
particular, concerning the accessibility of the C-
terminal region. According to a series of structural
studies,30–35 the C-terminal domain is not directly
involved in the fibril core but may have a role in the
stabilization or rearrangement of protofilaments
during fibril assembly. As the accessibility and
conformation of the C-terminal region of αSyn
would strongly influence the binding properties of
both NbSyn2 and NbSyn87, we explored by means
of ITC the binding of αSyn to fibrils formed for
different lengths of time. Our results reveal a
decrease in the apparent affinity of both nanobodies
for fibrils compared to monomeric αSyn, a difference
that becomes even larger when fibrils are incubated
for longer periods of time (Table 1), suggesting that
the conformation or accessibility of the C-terminal
domains varies upon fibril assembly and maturation.
The ITC experiments also indicate that the
apparent binding enthalpies for the nanobody:αSyn
fibril interactions become more favorable upon fibril
assembly and with the length of time for which the
fibrils are incubated. The ΔΔH values measured
between the nanobodies and αSyn monomers and
fibrils isolated after 2 days (F0,2d) and 6 days (F0,6d),
respectively, were measured to be −4.2 ± 0.5 and
−6.3 ± 1.0 kcal mol−1 for NbSyn87 and −0.5 ± 0.7
and −2.1 ± 0.9 kcal mol−1 for NbSyn2. This more
favorable trend of the apparent binding enthalpy
upon fibril formation and maturation suggests a
difference in the exposure or conformation of the
epitope located in the C-terminal domain upon fibril
assembly and incubation time. The further trend
toward more favorable binding enthalpy upon fibril
aging suggests that additional interactions or exo-
thermic processes take place when the nanobodies
bind to fibrils that were incubated for a longer period
of time; as we observe a decrease in binding affinity,
there must therefore be a greater entropic penalty for
binding to the more mature fibrils. This conclusion
suggests that either the nanobody:fibril complex
becomes increasingly more rigid with longer fibril
incubation times or a larger number of solvent
molecules become more highly structured in the
complexes of the nanobodies with more aged fibrils.
2407Nanobodies and α-Synuclein Fibril FormationThis effect is more pronounced for the binding of
NbSyn87 than for NbSyn2, an observation that can
be attributed to the fact that NbSyn87 binds closer to
the fibril core than NbSyn2, regardless of the origin of
these changes. However, our findings demonstrate
that the differences in thermodynamic parameters of
the binding allow a distinction between fibril samples
incubated for different lengths of time, indicating that
the detailed morphology of the fibrils evolves over
time as maturation occurs.55
Although no significant differences could be
detected between unseeded (F0) and seeded (F1)
fibrils by TEM imaging or ThT fluorescence mea-
surements (Fig. 5), the ITC studies of the binding of
both NbSyn87 and NbSyn2 to F1 generation fibrils
reveal a distinct bimodal binding isotherm, in contrast
to the classic sigmoidal, bimolecular binding iso-
therms observed for F0 fibrils. The degree of
bimodality is less marked for NbSyn2 relative to
NbSyn87 (Fig. 6), consistent with previous findings
that the residues more distant from the C-terminus
are closer to the fibril core and more likely to be
involved in interactions between protofilaments that
stabilize the fibrils.30–35 The differences in binding
isotherm between unseeded (F0) and seeded (F1)
fibril samples are therefore likely to indicate structural
differences that are too subtle to observe by TEM,
showing the sensitivity of the nanobody interactions
to the detailed morphologies of the fibrils.
Conclusions
In this study, we have compared the binding
properties of two nanobodies, NbSyn87 and
NbSyn2, to monomeric and fibrillar αSyn by the
use of NMR, ITC, CD and QCM methods. We have
shown that both nanobodies bind to specific regions
within the C-terminal domain of αSyn, comprising
approximately amino acids 118–131 and 137–140
for NbSyn87 and NbSyn2, respectively. The ability to
map these epitopes in detail and to measure the
affinities and stoichiometries of the binding of the
nanobodies to fibrillar species shows that it is
possible to distinguish between fibrillar samples at
different stages of maturation. Therefore, nanobo-
dies can act as powerful molecular probes to gain
insights into complex structures and can be used in
combination with conventional biophysical tech-
niques to shed light on subtle processes involved
in protein aggregation and fibril formation.
Materials and Methods
Isolation, expression and purification of nanobodies
and αSyn
Following the immunization of a llama with a point
mutant of αSyn (A53T αSyn), we isolated NbSyn87through phage display selection, essentially according to
previously published protocols.56,57 Immunization was
initiated by injection with purified αSyn (A53T) and boosted
at regular time intervals over a 6-week period. Lympho-
cytes were isolated and a nanobody phage display library
was constructed. The in vitro selection for binding to αSyn
resulted in the isolation of the binder NbSyn87, which was
subsequently sequenced and recloned in a modified
pHEN vector (pHEN6) containing a sequence coding for
six consecutive histidine residues at the C-terminus of the
nanobody. NbSyn87 and NbSyn2 (previously obtained
from dromedary immunization and phage display40) were
expressed in the periplasm of Escherichia coli and purified
using immobilized metal affinity chromatography and size-
exclusion chromatography according to published protocols.56
Expression and purification of the isotopically naturally
abundant full-length wild-type αSyn and the truncated
variant comprising amino acids 1–120, as well as samples
uniformly isotopically enriched in 15N and in 15N and 13C,
were carried out according to published protocols.58Preparation of αSyn fibrils
αSyn fibrils were prepared by incubating 70 μM mono-
meric αSyn at 37 °C in PBS buffer [10 mM phosphate
(pH 7.5), 100 mM NaCl and 0.1% NaN3] with agitation at
180 rpm and termed F0 fibrils. F0 fibrils that were harvested
after 2 or 6 days of incubation are referred to as F0,2d and
F0,6d, respectively. In order to separate the αSyn fibrils
from the remaining monomeric protein, we centrifuged the
protein solutions (30 min, 16,100g) and resuspended the
fibril-containing pellets in a volume of buffer that was equal
to the starting volume. This procedure was carried out
twice. In order to make a second generation of αSyn fibrils,
termed F1 fibrils, we prepared a solution of 70 μM αSyn in
PBS buffer and seeded it with 1% (v/v) previously prepared
F0,6d fibrils. This seeded sample was incubated at 37 °C
for 2 days, again with agitation at 180 rpm. These F1,2d
fibrils were used immediately for further experimental
investigations.Transmission electron microscopy
We applied 8-μl aliquots of undiluted samples containing
fibrils to Formvar-coated nickel grids (400-square mesh;
Agar Scientific, Stansted, UK), followed by a drop of 2%
(w/v) uranyl acetate. After a few seconds, the grids were
washed with deionized water (MilliQ) and allowed to dry.
Subsequently, electron micrographs were taken with a
JEM1010 instrument FEI Tecnai G2 (FEI North America,
Hillsboro, OR, USA).ThT measurements
We added 5-μl aliquots of fibril-containing solutions,
prepared in the absence or presence of nanobody, to a
60-μl volume of the ThT (20 μM) solution in PBS buffer
[10 mM phosphate (pH 7.5), 100 mM NaCl and 0.1%
NaN3]. ThT fluorescence was measured at excitation and
emission wavelengths of 440 and 480 nm, respectively,
using a Cary Eclipse fluorimeter (Varian, Walnut Creek,
2408 Nanobodies and α-Synuclein Fibril FormationCA, USA). To obtain the fluorescence signals originating
from ThT bound to the fibrils, we subtracted the fluores-
cence signal of a PBS/ThT sample in the absence of fibrils
from all measurements.Dot blot measurements
Dot blot assays were performed on the supernatants
and pellets of the fibril-containing samples after they were
centrifuged for 30 min at 16,100g; the pellets were
resuspended in a volume corresponding to that of the
original sample. Dot blots were performed by applying
sample aliquots (10 μl) to a nitrocellulose membrane
(Merck-Millipore, Consett, UK) mounted on a manifold.
Samples were vacuum filtered and washed with 200 μl of
PBS. Membranes were incubated in blocking solution of
5% non-fat skim milk in PBS for 60 min at room
temperature and then probed for 60 min at room temper-
ature with anti-αSyn antibody (Transduction Laboratories,
Lexington, KY, USA) at a 1:1000 dilution in blocking
solution. After incubation of the primary antibody, mem-
branes were washed three times in 0.01% Tween in PBS
for 10 min and subsequently incubated for 60 min at 25 °C
in a solution containing a secondary antibody (horseradish
peroxidase conjugated; Thermo Scientific, Rockford, IL,
USA) at a 1:5000 dilution and in 5% non-fat skim milk and
0.01% Tween in PBS. Chemiluminescence quantification
was obtained on a Typhoon Trio scanner (Amersham
Bioscience, Piscataway, NJ, USA), and the images were
analyzed with the program ImageQuant TL v2005 software
provided by the manufacturer.NMR spectroscopy
All NMR experiments were performed using Bruker
Avance 500-MHz and 700-MHz spectrometers (Bruker,
UK) equipped with cryo-probes. All NMR data were
subsequently processed using NMRPipe, 59 and
SPARKY† was used for analysis of the data. 15N–1H
HSQC measurements of 15N-labeled αSyn were carried
out at a 1H frequency of 500 MHz, and spectra of 15N-
labeled αSyn were recorded in the presence and absence
of 1 molar equivalent of added unlabeled nanobody. All
experiments were carried out in 10 mM phosphate buffer
and 150 mM NaCl (pH 7.4) and at 283 K. The amide
resonances and Cα and Cβ chemical shifts of αSyn have
been defined previously,50,60 and the N, H, CO, Cα and Cβ
chemical shifts of the αSyn resonances in its complex with
NbSyn87 were assigned using a series of standard 3D
experiments, mainly, HNCO, CBCA(CO)NH and HNCACB
spectra. Sample integrity checks were performed between
and after each 3D experiment by recording 15N–1H HSQC
spectra. The assignments of αSyn bound to NbSyn2 have
been reported previously.40Isothermal titration calorimetry
Calorimetric data were recorded using an iTC200
calorimeter (MicroCal, Northampton, MA, USA). We
titrated 40-μl solutions of NbSyn87 or NbSyn2, each at a
concentration of 150 μM, in 2-μl aliquots into the calori-
metric cell containing a standard volume of 203 μl of a10 μM monomeric αSyn solution. Similar experiments
were performed with the series of synthetic peptides
(Genemed Synthesis Inc., San Antonio, TX, USA)
designed to span different stretches of the αSyn sequence
in the C-terminal region. Prior to the ITC experiments, both
the nanobody and αSyn, or the designed peptide, were
dialyzed into, or dissolved in, exactly the same buffer
containing 10 mM phosphate and 150 mM NaCl at a pH of
7.4. Injections of the solutions of the nanobodies into the
sample cell were performed at 150-s intervals at the
desired temperature. Injections of the titrant into a cell that
contained only buffer solutions were subtracted from the
other binding experiments to correct for the heat generated
by dilution effects. The thermodynamic analysis was
performed with MicroCal analysis software (Origin 7.0)
using a 1:1 bimolecular binding model. The temperature
dependence measurement between 20 and 37 °C of the
binding enthalpy (ΔHb) allowed the calculation of changes
in heat capacity of binding through the relationshipΔCp,b =
δΔHb/δT, for which Cp,b is the heat capacity of binding,
Hb is the binding enthalpy and T is the absolute
temperature (K).
Similar ITC experiments were performed with unseeded
(F0) and seeded (F1) αSyn fibrils. In order to determine
the total number of αSyn molecules present in the fibril
solution, we dissolved the fibrils in 4 M guanidinium
chloride (Gdn-HCl) and measured the absorbance at
280 nm using an extinction coefficient of 7438 M−1 cm−1.
This value was obtained by measuring the absorbance of
equimolar samples of αSyn, dissolved either in water or in
4 M Gdn-HCl buffer, according to the Beer–Lambert
relationship (A = ε.l.C), resulting in the following equation:
εGdn-HCl = εH20.AGdn-HCl/AH2O.Circular dichroism spectroscopy
Samples of αSyn, NbSyn87 and NbSyn240 were
prepared at a concentration of 20 μM, and equimolar
mixtures of αSyn (20 μM) and each nanobody (20 μM)
were prepared in 10 mM phosphate buffer (pH 7.4) and
150 mM NaCl, from more concentrated stock solutions of
αSyn and each nanobody. CD measurements were
performed on a Jasco J-810 spectrometer (Jasco,
Essex, UK) using a cuvette with a 0.1-cm path length.
Spectra were recorded between 250 and 200 nm at 25 °C.
We averaged 20 scans without smoothing but corrected
them for the spectra of the buffer. The secondary structure
perturbations associated with formation of each nano-
body:αSyn complex were monitored by subtracting the
spectra of both free αSyn and the appropriate nanobody
from the spectrum of the nanobody:αSyn sample.
Quartz crystal microbalance measurements
QCM sensors, with αSyn fibril fragments attached to the
surfaces, were prepared according to published
protocols.52 Fibrils of full-length αSyn were obtained by
incubating 70 μMmonomeric αSyn in PBS buffer at pH 7.4
and 37 °C for 2 days under agitation at 180 rpm. Fibrils
made of the 1–120 (truncated) αSyn variant were obtained
by incubating 400 μM (truncated) monomeric αSyn at
45 °C in PBS buffer under heavy stirring for 2 days. The
presence of fibrils was confirmed by atomic force
2409Nanobodies and α-Synuclein Fibril Formationmicroscopy of the samples. The average length of the
fibrils was decreased by fragmentation induced by a probe
sonicator (4–6 min at 20% amplitude on a 500-W
ultrasonic homogenizer; Cole Parmer, Hanwell, UK).
Then, 0.5 mg of Traut's reagent (2-imminothiolane;
Sigma Aldrich, Gillingham, UK) was added to 500 μl of
fibril suspension at 70–80 μM. After incubation for 5 min,
100 μl of the resulting fibril suspension was allowed to
adsorb onto the surface of a gold-coated QSX 301 QCM
sensor (Q-Sense, Västra Frölunda, Sweden) for 60 min.
Then, to avoid non-specific adsorption in the subsequent
experiments, the gold surface that was not covered by
fibrils was modified with a monolayer of an inert
polyethylene glycol thiol CH3O(CH2CH2O)6SH (Polypure,
Oslo, Norway) incubated in a 0.5% solution of polyethyl-
ene glycol thiol in PBS for 60 min. Finally, the sensor was
inserted into the QCM instrument and left to equilibrate in
PBS until a stable baseline was obtained. Before the
nanobody binding experiments, the sensors with the
attached seed fibrils were incubated for ~1 h with a
solution of 20 μM soluble αSyn, in order to increase the
total mass of fibrils attached to the surface and therefore to
maximize the signal stemming from the binding of nano-
body to the surface-bound fibrils.
Real-time monitoring of fibril binding was carried out at
37 °C, using a Q-Sense E4 QCM by exposing the QCM
sensors to a solution containing 5 μM NbSyn87 and/or
NbSyn2. The temperature in the reaction chamber that has
a volume of 40 μl was kept stable to within 0.05 °C.Acknowledgements
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